Skip to content

A retrospective study of Recombinant Human Prourokinase for injection in the treatment of acute ST Segment Elevation Myocardial Infarction (STEMI)

A retrospective study of Recombinant Human Prourokinase for injection in the treatment of acute ST Segment Elevation Myocardial Infarction (STEMI)

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000034363
Enrollment
Unknown
Registered
2020-07-03
Start date
2020-09-01
Completion date
Unknown
Last updated
2020-07-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

STEMI

Interventions

case series:Recombinant Human Prourokinase

Sponsors

Tianjin Chest Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Aged >=18 years; 2. Patients confirmed ST-segment elevation myocardial infarction within 24 hours of onset; 3. Patients received thrombolytic therapy.

Exclusion criteria

Exclusion criteria: 1. Patients with recent (30 days) active bleeding (gastrointestinal ulcer, hemoptysis, hemorrhoids, hematochezia, etc.); 2. Surgery or biopsy within 3 months, cardiopulmonary resuscitation (extracorporeal heart compression, intracardiac injection, endotracheal intubation),vascular puncture of the compression site should not be performed and with history of trauma; 3. Unsatisfactory blood pressure control (blood pressure 180/110mmhg) or aortic dissecting aneurysm cannot be excluded; 4. Patients with history of hemorrhagic stroke and vascular embolism (including TIA); 5. Shock patients who do not respond to dilatation therapy or vasopressors; 6. Pregnant women, patients with bacterial endocarditis, patients with mitral valve disease and atrial fibrillation and high suspicion of thrombus in the left ventricle; 7. Patients with hemorrhagic disease or bleeding tendency, severe liver and kidney dysfunction, and progressive disease; 8. Diabetic patients with retinopathy; 9. Patients with consciousness disorder.

Design outcomes

Primary

MeasureTime frame
Amount of dissolved suppository;Whether the chest pain is relieved;The ST segment of electrocardiogram decreased by =50%;Target blood flow (TIMI) grade;Target blood flow (TIMI) grade;Clinical MACE Events (in-hospital);

Countries

China

Contacts

Public ContactLi Chunjie, Fu Xianghua, Huo Yong

Tianjin Chest Hospital

ykwn@sina.com+86 13820600988

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026